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Abstract
Background The effect of implantable cardioverter-defibrillator (ICD) therapy in patients with heart failure with reduced 
ejection fraction (HFrEF) and diabetes is not fully elucidated.
Methods We examined the effect of ICD therapy on sudden cardiac death, cardiovascular death and all-cause mortality, 
according to diabetes status at baseline in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). The outcomes were 
analyzed by use of cumulative incidence curves and Cox regressions models.
Results Of the 1676 patients randomized to an ICD or placebo, 540 (32%) had diabetes at baseline. Patients with diabetes 
were slightly older (61 vs 58 years) and were more often in NYHA class III (37% vs 28%). ICD therapy did not reduce the 
risk of sudden cardiac death in HFrEF patients with diabetes (HR = 0.85; 95% CI 0.52–1.40); even though these patients had 
a higher risk of sudden cardiac death compared to patients without diabetes (HR = 1.73 95% CI 1.22–2.47). By contrast, ICD 
therapy did reduce sudden cardiac death in HFrEF patients without diabetes (HR = 0.26; 95% CI 0.15–0.46); Pinteraction=0.002. 
The findings for cardiovascular and all-cause death were similar.
Conclusion ICD therapy did not reduce the risk of sudden cardiac death (or, as a consequence, all-cause death) in HFrEF 
patients with diabetes. Conversely, an ICD reduced the risk of sudden death in patients without diabetes, irrespective of 
etiology.
Keywords Implantable cardioverter-defibrillator · Heart failure with reduced ejection fraction · Diabetes · Sudden cardiac 
death
Introduction
Patients with heart failure, reduced ejection fraction 
(HFrEF) and diabetes have a higher risk of adverse cardio-
vascular outcomes compared to HFrEF patients without 
diabetes [1–3]. This elevated risk includes a higher rate of 
sudden, presumed arrhythmic, cardiac death [4, 5]. Use of 
an implantable cardioverter-defibrillator (ICD) has been 
shown to reduce the risk of sudden cardiac death, and over-
all mortality, in patients with HFrEF. However, there is less 
certainty about the benefit of an ICD in patients with a non-
ischemic etiology compared to those with an ischemic etiol-
ogy [6, 7]. Patients with an ischemic etiology have a higher 
risk of sudden death than those with a non-ischemic etiology 
[6, 7].The effect of ICD therapy in HFrEF patients with dia-
betes, with and without underlying ischemic heart disease, 
has not been described, although this is clearly an impor-
tant question given the frequent overlap between HFrEF 
and diabetes, the potentially different response to therapy 
in HFrEF patients with diabetes and the especially high risk 
of sudden death faced by individuals with both diabetes and 
an ischemic etiology. We examined these questions in the 
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 
the single large trial which demonstrated the benefit of this 
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therapy in patients with HFrEF due to both ischemic and 
non-ischemic causes.
Methods
Study design and population
The design and primary results of SCD-HeFT are published 
[6]. In brief, in SCD-HeFT, 2521 patients in New York Heart 
Association (NYHA) functional class II or III, with a left 
ventricular ejection fraction (LVEF) ≤ 35%, were randomly 
assigned to placebo, amiodarone or ICD therapy in a 1:1:1 
ratio. ICD therapy, but not amiodarone, reduced the primary 
endpoint of all-cause death. We used the public-use copy of 
the SCD-HeFT database obtained from the National Heart, 
Lung, and Blood Institute which sponsored the trial.
Definition of diabetes and etiology
For this analysis, patients were categorized according to 
whether they had a history of diabetes/were treated with 
glucose-lowering drugs at baseline or not. Ischemic or non-
ischemic etiology was determined by the investigators.
Outcomes
The primary endpoint of this study was that used in SCD-
HeFT, i.e., all-cause mortality. Cardiovascular death, sudden 
cardiac death, and death due to heart failure were evaluated 
as secondary outcomes. Outcomes were evaluated accord-
ing to HF etiology, NYHA class, and estimated glomerular 
filtration rate (eGFR)
Statistical analysis
Baseline characteristics according to diabetes status were 
described using proportions for categorical variables and 
mean values with standard deviations or medians with 
quartiles for continuous variables. Differences in baseline 
characteristics according to diabetes status were tested by 
use of χ2-test for categorical variables and ANOVA or 
Kruskal–Wallis’s test for continuous variables. Changes 
in LVEF were summarized by use of medians with quar-
tiles and differences evaluated by use of quantile regression 
adjusted for baseline values. Kaplan–Meier curves for all-
cause mortality and cumulative incidence curves for cardio-
vascular death and sudden cardiac death were estimated and 
differences between groups were compared by log rank and 
Gray’s test, respectively. Cox proportional hazard models 
were used to compare the risk according to diabetes status 
for all death-related outcomes. The adjusted Cox regression 
models included information on age, gender, randomization 
to ICD implantation, NYHA class, LVEF, duration of heart 
failure, heart failure etiology, systolic blood pressure, cre-
atinine, history of atrial fibrillation, stroke and pulmonary 
disease. Log [-log(survival)] curves were used to evaluate 
the proportional hazard assumption. Diabetes status, heart 
failure etiology and NYHA class were tested for interac-
tions with randomization to ICD implantation in relation to 
all outcomes. The interaction of eGFR and treatment effect 
according to diabetes status on all-cause mortality was ana-
lyzed by multivariable fractional polynomials with extension 
for interactions.
P values < 0.05 were considered significant. Analyses 
were performed by Stata version 15 and R version 3.3.2.
Results
Baseline characteristics
Of the 1676 patients randomized to an ICD or placebo, 540 
(32%) had diabetes at baseline. Patients with diabetes were 
slightly older (61 vs 58 years), were more often in NYHA 
class III (37% vs 28%), had worse kidney function (median 
eGFR: 68 vs 71 mL/min per 1.73 m2), and higher weight 
(89 vs 84 kg), compared to those without diabetes (Table 1). 
History of hypertension (68% vs 50%), myocardial infarction 
(76% vs 71%), stroke (8% vs 6%) and treatment with diuret-
ics (89% vs 81%) was more common among patients with 
diabetes. These findings remained consistent when patients 
in the amiodarone arm of the trial were added (Supplemen-
tary table 1).
Complications during ICD implantation
Patients with diabetes had similar risk of ICD-related infec-
tions and a lower risk of bleeding and pneumothorax than 
patients without diabetes. Specifically, infection compli-
cated implantation in 20 (3.5%) patients without diabetes, 
compared to 9 (3.1%) patients with diabetes (p = 0.76); the 
respective numbers for bleeding were 29 (5.1%) vs. 4 (1.5%), 
p = 0.02 and for pneumothorax 9 (1.6%) vs. 0 (0%), p = 0.04.
Change in left ventricular ejection fraction 
after randomization
Patients with diabetes had a slightly but significantly higher 
LVEF at baseline, compared to patients without diabetes, 
and also marginally but significantly greater increase in 
LVEF during follow-up: median change from baseline to 
12 months (n = 1159) + 4 [IQR 0.0, 12.5] in patients with-
out diabetes and + 5 [− 1.0, 12.5] in patients with diabetes, 
p = 0.004; the corresponding changes at 30 months (n = 777) 
were: + 5 [0.0, 15.0] vs + 6 [0.0, 16.0], respectively, 
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p = 0.005. As a result, 32.5% of patients with diabetes (com-
pared to 30.0% without diabetes) had a LVEF > 35% after 
approximately 12 months of follow-up and 40% (compared 
with 36%) at 30 months.
Clinical outcomes according to diabetes status
During a median follow-up of 46 months (Q1-Q3:35–55), 
sudden cardiac death occurred in 63 (12%) patients with dia-
betes and 71 (6%) without. Death from cardiovascular causes 
occurred in 128 (24%) patients with diabetes and in 161 
(14%) patients without; 187 (35%) patients with diabetes 
died from any cause, compared to 239 (21%) patients with-
out diabetes. In adjusted analyses, diabetes was associated 
with a higher risk of sudden cardiac death (HR = 1.73 95% 
CI 1.22–2.47; p = 0.002), cardiovascular death (HR = 1.52; 
95% CI 1.19–1.93; p = 0.001) and all-cause mortality 
(HR = 1.50; 95% CI 1.23–1.83; p < 0.0001); Table 2.
Effect of ICD therapy according to diabetes status
ICD therapy did not reduce the risk of sudden cardiac 
death in HFrEF patients with diabetes (HR = 0.85; 95% 
CI 0.52–1.40). By contrast, ICD therapy did reduce sud-
den cardiac death in HFrEF patients without diabetes 
(HR = 0.26; 95% CI 0.15–0.46); Pinteraction=0.002. The 
effects of ICD therapy on any cardiovascular death and 
death from heart failure are shown in Fig. 1. Examin-
ing all-cause mortality, 84 patients (32%) with diabetes 
died in the ICD group compared to 103 patients (37%) 
with diabetes in the placebo group; HR = 0.94; 95% CI 
0.70–1.25; p = 0.65 (Fig. 2). Among those without diabe-
tes, 98 patients (17%) died in the ICD group, compared to 
141 patients (25%) without diabetes in the placebo group; 
HR = 0.68; 95% CI 0.52–0.88; p = 0.003 (Fig. 2), p for 
interaction = 0.11 (Fig. 1).
Patient level data on appropriate and inappropriate ICD 
discharges were not available.
Table 1  Baseline characteristics 
of patients in the placebo and 
ICD group
Q-quartile, ICD implantable cardioverter defibrillator, ACE angiotensin-converting enzyme, ARB angioten-
sin-receptor blocker, eGFR estimated glomerular filtration rate
a At baseline
No diabetes Diabetes P values
Patients, n (%) 1136 (68) 540 (32)
Age, median [Q1–Q3] 58 [50 68] 61 [53, 68] 0.0095
Men, n (%) 883 (78) 411 (76) 0.4606
White, n (%) 890 (78) 393 (73) 0.0218
ICD implantation, n (%) 570 (50) 259 (48) 0.3971
NYHA class III, n (%) 314 (28) 202 (37) 0.0001
Ischemic heart failure etiology, n (%) 551 (49) 333 (62) 0.0001
Left ventricular ejection fraction, median [Q1–Q3] 23.5 [19, 30] 25 [20, 30] 0.0074
Systolic blood pressure, mmHg, median [Q1–Q3] 117 [104, 130] 120.0 [108.0, 135.0] 0.0011
Diastolic blood pressure, mmHg, median [Q1–Q3] 70 [62, 80] 70 [60, 80] 0.3732
Weight, Kg, median [Q1–Q3] 84 [73, 98] 89 [77, 104] 0.0001
Heart rate, beats/min, median [Q1–Q3] 72 [64, 83] 77 [68, 86] 0.0001
eGFR, mL/min/1.73 m2, median [Q1–Q3] 71 [57, 85] 68 [52, 82] 0.0007
Medical history, n (%)
 Atrial fibrillation/flutter 170 (15) 88 (16) 0.4803
 Hypertension 564 (50) 367 (68) 0.0001
 Myocardial infarction 478 (71) 282 (76) 0.0402
 Stroke 64 (6) 45 (8) 0.0362
 Pulmonary disease 213 (19) 120 (22) 0.0959
Medicationa, n (%)
 ACE inhibitor or ARB 1093 (96) 517 (96) 0.641
 Β-Blocker 788 (69) 369 (68) 0.6691
 Mineralocorticoid-receptor antagonist 210 (19) 107 (20) 0.5162
 Diuretic 923 (81) 480 (89) 0.0001
 Digoxin 763 (67) 378 (70) 0.2447
 Insulin 0 (0) 198 (37) –
 Oral hypoglycemic agents 0 (0) 325 (60) –
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Effect of ICD implantation according to diabetes 
status and kidney function
The reduction in sudden cardiac death with an ICD was 
apparent in patients without diabetes, irrespective of kidney 
function, although attenuated in no-diabetes patients with 
chronic kidney disease (CKD) (Fig. 3 and Supplementary 
Fig. 1). By contrast, the effect of ICD therapy on sudden 
cardiac death in patients with diabetes was absent in patients 
with concomitant CKD and attenuated in those with pre-
served renal function, compared to no diabetes patients with 
an eGFR > 60 mL/min/1.73 m2 (Fig. 3). Similar findings 
were observed when eGFR was examined as a continuous 
variable (Supplementary Fig. 1).
All-cause mortality was lower in the ICD group, com-
pared with the placebo group, in patients without diabe-
tes, irrespective of renal function category. By contrast, 
ICD treatment did not clearly reduce all-cause mortality in 
patients with diabetes but without CKD. In patients with 
both diabetes and CKD, mortality was higher in the ICD 
group than in the placebo group (Fig. 3).
Effect of ICD implantation according to diabetes 
status and ischemic vs. non‑ischemic etiology
The reduction in sudden cardiac death with an ICD was 
apparent in patients without diabetes, irrespective of etiol-
ogy (Fig. 4). By contrast, there was no clear effect of ICD 
therapy on sudden cardiac death in patients with diabe-
tes, whether the etiology of HFrEF was ischemic or non-
ischemic (Fig. 4). The effect of ICD therapy on sudden 
cardiac death was significantly modified by diabetes status 
overall, according to etiology and CKD status and in relation 
to NYHA class (Fig. 1).
All-cause mortality was lower in the ICD group, com-
pared with the placebo group, in patients without diabetes, 
irrespective of etiology (ischemic vs. non-ischemic). By 
contrast, ICD treatment did not reduce all-cause mortality 
in patients with diabetes, irrespective of etiology.
Effect of amiodarone according to diabetes status
In the amiodarone group, 97 (39%) with diabetes died com-
pared to 103 (37%) with diabetes in the placebo group; 
HR = 1.19; 95% 0.90–1.57; p = 0.22; Fig. 1. In patients 
without diabetes, 143 patients (24%) died in the amiodarone 
group compared to 141 patients (25%) without diabetes in 
the placebo group; HR = 1.01; 95% CI 0.80–1.27; p = 0.96 
(Fig. 1).
Effect of amiodarone according to diabetes status 
and ischemic vs. non‑ischemic etiology
Overall, the effect of amiodarone, compared with placebo, 
did not differ according to diabetes status, etiology, NYHA 
class or CKD status (Supplementary Fig. 2).
Discussion
In this retrospective subgroup analysis of SCD-HeFT, ICD 
therapy did not reduce the risk of sudden cardiac death, 
and therefore the risk of death from any cause, in HFrEF 
patients with diabetes although these patients were at high 
Table 2  Event rates and hazard ratios for all outcomes according to diabetes status of patients in the placebo and ICD group
HR hazard ratio, py person years, CV cardiovascular, ref reference
a Adjusted for age, gender, randomization to ICD implantation, NYHA class, left ventricular ejection fraction, duration of HF, HF etiology, sys-
tolic blood pressure, creatinine, history of atrial fibrillation, stroke and pulmonary disease
Events (n) Crude rate per 100 
py (95% CI)
Unadjusted HR (95% CI) p values Adjusted  HRa (95% CI) p values
All-cause mortality
 Diabetes 187 10.8 (9.4–12.5) 1.80 (1.49–2.18) < 0.0001 1.50 (1.23–1.83) < 0.0001
 No diabetes 239 6.1 (5.3–6.9) 1.00 (ref.) 1.00 (ref.)
CV death
 Diabetes 128 7.4 (6.2–8.8) 1.82 (1.44–2.30) < 0.0001 1.52(1.19–1.93) 0.001
 No diabetes 161 4.1 (3.5–4.8) 1.00 (ref.) 1.00 (ref.)
Sudden cardiac death
 Diabetes 63 3.7 (2.9–4.7) 2.02 (1.44–2.83) < 0.0001 1.73 (1.22–2.47) 0.002
 No diabetes 71 1.8 (1.4–2.3) 1.00 (ref.) 1.00 (ref.)
Non-sudden CV death
 Diabetes 124 7.2 (6.0-8.6) 1.71 (1.36–2.16) < 0.0001 1.42 (1.11–1.80) 0.005
 No diabetes 168 4.3 (3.7–4.9) 1.00 (ref.) 1.00 (ref.)
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Fig. 1  Hazard ratios for the 
comparison of ICD therapy vs 
placebo
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risk of sudden, presumed arrhythmic, death. By contrast, 
ICD therapy did reduce the risk of sudden cardiac death, and 
all-cause mortality, in HFrEF patients without diabetes. This 
difference in outcomes with ICD therapy was not explained 
by etiology (ischemic versus non-ischemic) of HFrEF.
The explanation for the lack of mortality benefit in 
patients with diabetes is uncertain although the issue of 
competing risks needs to be considered as it is more rel-
evant with an ICD than other therapies for heart failure 
and more relevant in patients with diabetes than in those 
without. Specifically, ICD therapy only reduces one mode 
of cardiovascular death, leaving the competing risk of 
other cardiovascular, as well as non-cardiovascular causes 
of death. Patients with diabetes are at greater risk of non-
cardiovascular death than patients without diabetes, limit-
ing the impact of any cardiovascular treatment on overall 
mortality. While the latter was true even in the relatively 
young patients enrolled in SCD-HeFT, there was only a 
small excess of non-cardiovascular death among individu-
als with diabetes. However, and more importantly, there 
Fig. 2  Risk of death among patients with and without diabetes
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was no evidence of a bidirectional effect of ICD therapy 
on different modes of cardiovascular death in patients with 
diabetes. Quite simply, ICD treatment was of no benefit in 
patients with diabetes because this therapy had no effect on 
sudden cardiac death (and the benefit of device therapy in 
patients without diabetes was attributable to the reduction 
in sudden cardiac death with an ICD). There was no sug-
gestion that ICD therapy increased non-sudden cardiovas-
cular death, particularly death from heart failure, in patients 
with diabetes (whereas there was some indication of this in 
patients without diabetes).
Because of recent debate about the value (or lack of 
value) of ICDs in patients with non-ischemic etiology, we 
also examined the interaction between diabetes status and 
etiology (ischemic versus non-ischemic) and effect of ICD 
therapy on outcomes. We found that an ICD reduced the risk 
of sudden death in patients without diabetes, irrespective of 
etiology. In patients with diabetes, ICD therapy had no effect 
Fig. 3  Risk of death according to diabetes status and eGFR ≥ 60 mL/min/1.73 m2 (A + C) or eGFR < 60 mL/min/1.73 m2 (B + D)
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on sudden death, and this lack of benefit was true for both 
ischemic and non-ischemic etiologies. This finding is a par-
ticularly concerning for HFrEF patients with the relatively 
common combination of diabetes and an ischemic etiology, 
as they are at especially high risk of sudden cardiac death.
Assuming our findings are correct, they raise the pos-
sibility that ICDs are less effective at aborting ventricular 
arrhythmias in HFrEF patients with diabetes or, secondly, 
that a substantial proportion of adjudicated sudden cardiac 
deaths in HFrEF patients with diabetes are caused by mech-
anisms other than ventricular arrhythmias. Regarding the 
first possibility, comparison with the Multicenter Auto-
matic Defibrillator Implantation Trial II (MADIT II), the 
pivotal ICD trial in patients after myocardial infarction is 
instructive [8]. In MADIT II, ICD treatment appeared to 
reduce all-cause mortality by a similar amount in patients 
with (n = 433) and without diabetes (n = 798) [9]. In other 
words, it was possible to show that ICDs are of benefit in 
Fig. 4  Risk of death according to ischemic (A + C) and non-ischemic (B + D) HF etiology and diabetes
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patients with diabetes in a related, although not identical, 
population. If we assume most sudden deaths in chronic 
heart failure are caused by ventricular arrhythmias, the lack 
of benefit of an ICD in HFrEF patients (compared to those 
with myocardial infarction) suggests that development of the 
syndrome of symptomatic heart failure, weeks, months or 
years after infarction, is associated with changes in the dia-
betic heart, such as deposition of glycoproteins, extracellular 
matrix accumulation, interstitial edema, myocyte hypertro-
phy and myocyte loss, that attenuate the effect of electrical 
therapy [10, 11]. Alternatively, the proportion of ventricular 
arrhythmias arising because of acute ischemia is likely to 
be less in chronic HFrEF than after myocardial infarction, 
given the much higher rate of occurrence of acute coronary 
syndromes in high-risk infarct survivors, compared with 
chronic HFrEF patients [12–17]. A further potential effect-
modifier is renal function. The benefit of an ICD is known 
to be reduced in patients with renal impairment and HFrEF 
patients with diabetes have worse renal function than HFrEF 
patients without diabetes [18]. We observed that SCD-HeFT 
patients with both HFrEF and diabetes were at especially 
high risk and appeared to get no benefit at all from an ICD 
(indeed, among these patients, those with a device did worse 
than those without a device). However, even in patients with 
preserved kidney function, the benefit of an ICD was less in 
patients with diabetes than in those without.
Another relevant factor may be the considerable increase 
in LVEF over time in patients in SCD-HeFT, an increase 
which was slightly but significantly greater in patients with 
diabetes (+ 5% at 1 year), compared to those without (+ 4%). 
By a year after randomization, 31% patients with diabetes 
had increased their LVEF to > 35% compared to 27% of 
those without diabetes. Although these differences were 
relatively small (and confounder by survivor bias), they may 
also have contributed to a lower risk of arrhythmias and less 
potential for benefit from an ICD in patients with diabetes.
Alternatively, a significant proportion of sudden cardiac 
deaths in HFrEF patients with diabetes, may not be caused 
by ventricular arrhythmias. In SCD-HeFT, the ICDs used 
were single chamber systems programmed only to shock 
and not to pace. Consequently, these devices did not protect 
against bradycardia-related events.
Another potential contributor to lack of overall benefit 
of ICD therapy in patients with diabetes, compared to those 
without, might be a greater complication rate during device 
implantation in individuals with diabetes, resulting in less 
net benefit. However, we found that the complication rate 
was somewhat less in patients with diabetes, compared to 
those without, at least in the short-term (and the overall 
number of complications was small). A recent pooled analy-
sis of 4 primary prevention ICD trials, including SCD-HeFT, 
also reported this trend [19].
Lastly, there is the possibility that some sudden deaths 
in HFrEF patients with diabetes are not related to a primary 
cardiac arrhythmia. These may be cardiovascular in nature 
(such as stroke) or due to other causes such as hypoglycemia; 
here it is notable that 37% of patients with diabetes in SCD-
HeFT were treated with insulin at baseline [20, 21].
One other finding in this study is worthy of comment. 
Amiodarone therapy, which was ineffective overall, led to a 
numerically higher death rate in patients with diabetes, when 
compared to placebo. Amiodarone did not increase mortal-
ity, compared with placebo, in patients without diabetes.
Limitations
This is a post hoc analysis and, as such, warrants caution in 
the interpretation of the results. One concern is the relatively 
small number of patients with diabetes (n = 540). However, 
the number of patients with diabetes in MADIT II was 
smaller and yet that trial showed a benefit of ICD therapy, 
suggesting that our finding of no effect was not due to lack 
of power [9]. A recent pooled analysis of four primary pre-
vention trials also found no overall benefit of ICD therapy in 
patients with diabetes but that analysis mixed patients with 
HFrEF and myocardial infarction, populations with different 
risks of sudden and non-sudden cardiovascular death and 
potentially different mechanisms underlying sudden cardiac 
death [19]. That report did not describe the effect of ICD 
therapy on sudden cardiac death versus non-sudden cardio-
vascular death, which is crucial in understanding potentially 
differential effects of this treatment, i.e., an ICD can only 
reduce all-cause mortality by reducing sudden cardiac death 
(substantially) without simultaneously increasing the risk of 
non-sudden death.
We also did not have data on rates of device therapy 
and whether this was appropriate or inappropriate. How-
ever, another trial, the Multicenter Automatic Defibrilla-
tor Implantation Trial–Reduce Inappropriate Therapy trial 
(MADIT-RIT), demonstrated less inappropriate therapy in 
patients with diabetes compared to those without [22].
Conclusion
ICD therapy did not reduce the risk of sudden cardiac death 
(or, as a consequence, all-cause death) in HFrEF patients 
with diabetes. Conversely, an ICD reduced the risk of sud-
den death in patients without diabetes, irrespective of etiol-
ogy. This may be because ICDs are less effective at aborting 
ventricular arrhythmias in HFrEF patients with diabetes or 
that some episodes of sudden death in these patients may be 
caused by other cardiac mechanisms (e.g., bradycardia) or 
non-cardiac events (e.g., hypoglycaemia).
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